Biomarkers Linked to Elevated T2D MACE Risk

A secondary analysis of a large landmark clinical trial of how the sodium-glucose cotransporter 2 inhibitor dapagliflozin effects cardiovascular risk has identified two biomarkers that can help better determine which patients with type 2 diabetes and cardiovascular disease risk would derive the most benefit from the drug.

Although NT-proBNP is typically measured to diagnose heart failure, and hsTnT to diagnose acute MI, Dr. Morrow pointed out that this analysis demonstrated the potential for using the two tests to evaluate risks in T2D patients. trial. The patients had T2D and multiple risk factors for atherosclerotic cardiovascular disease or established ASCVD . All patients had available blood samples and the data were collected from May 2013 to September 2018.

"We have previously shown that among patients with T2D who have high risk indicators, such as prior MI or long-standing diabetes, dapagliflozin also appeared to reduce MACE," Dr. Morrow said."In this study, we find that these two widely available biomarkers also identify a high-risk group who may have even more potential benefits from treatment with an SGLT2i."

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Verdict reached in penalty phase of trial of NYC bike path terrorist | CNNThe jury in the penalty phase of the trial of a terrorist convicted of committing a 2017 attack for ISIS that killed eight on a New York City bike path has told the judge it was unable to reach a unanimous decision. Of course not! It’s NY! They are a crime ridden s-hole that democrats have let become lawless! Just send him to Gitmo. What it was made for I’ll help you. What about a death sentence?
Source: CNN - 🏆 4. / 95 Read more »